Advanced search
Publication Cover
Cancer Investigation Volume 42, 2024 - Issue 1
Submit an article Journal homepage
40
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma

Cedric Lebaclea Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA;b Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Le Kremlin Bicetre, FranceCorrespondence[email protected]
View further author information
,
Aydin Poolia Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Brian Shucha Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Nagesh Raoc Department of Pathology and Lab Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Karim Chamiea Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Nils Kroegerd Department of Urology, University Medicine Greifswald, Greifswald, GermanyView further author information
,
Izak Faienaa Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Sandy Liue Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, California, USAView further author information
,
Erika L. Wooda Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Arie Belldegruna Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
,
Alexandra Drakakia Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA;e Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, California, USAView further author information
&
Allan J. Pantucka Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USAView further author information
 show all
Pages 97-103 | Received 20 Sep 2023, Accepted 17 Jan 2024, Published online: 05 Feb 2024

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. Cited in: PMID: 29313949. doi:10.3322/caac.21442.
  • Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014;65(6):1086–1092. Cited in: PMID: 23916693. doi:10.1016/j.eururo.2013.07.031.
  • EAU Guidelines. Renal cell carcinoma. EAU Guidel Edn Present EAU Annu Congr Cph 2018 ISBN 978-94-92671-01-1 2018. [accessed September 5, 2018]. https://uroweb.org/guideline/renal-cell-carcinoma/#8.
  • Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA Guideline. J Urol. 2013;190(2):407–416. Cited in: PMID: 23665399. doi:10.1016/j.juro.2013.04.121.
  • Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131–133. Cited in: doi:10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G.
  • Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27(5):746–753. Cited in: PMID: 19124809. doi:10.1200/JCO.2007.15.8345.
  • Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol. 1995;103(5):624–635. Cited in: PMID: 7741111. doi:10.1093/ajcp/103.5.624.
  • Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol. 1997;183(2):151–155. Cited in: PMID: 9390026. doi:10.1002/(SICI)1096-9896(199710)183:2<151::AID-PATH928>3.0.CO;2-R.
  • Elfving P, Mandahl N, Lundgren R, Limon J, Bak-Jensen E, Fernö M, et al. Prognostic implications of cytogenetic findings in kidney cancer. Br J Urol. 1997;80(5):698–706. Cited in: PMID: 9393289. doi:10.1046/j.1464-410x.1997.00439.x.
  • Brunelli M, Eccher A, Gobbo S, Ficarra V, Novara G, Cossu-Rocca P, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol. 2008;21(1):1–6. Cited in: PMID: 17906617. doi:10.1038/modpathol.3800967.
  • Moch H, Presti JC, Jr, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, Waldman FM. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56(1):27–30. Cited in: PMID: 8548768.
  • Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. Cited in: PMID: 23792563. doi:10.1038/nature12222.
  • Hakimi AA, Mano R, Ciriello G, Gonen M, Mikkilineni N, Sfakianos JP, et al. Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. J Urol. 2014;192(1):24–29. Cited in: PMID: 24518768 doi:10.1016/j.juro.2014.01.088.
  • Gunawan B, Huber W, Holtrup M, von Heydebreck A, Efferth T, Poustka A, et al. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res. 2001;61(21):7731–7738. Cited in: PMID: 11691785.
  • Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. AJCC Cancer staging manual. 8th ed. Springer International Publishing; 2017. https://link.springer.com/book/9783319406176.
  • Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–1504. Cited in: PMID: 24025520. doi:10.1097/PAS.0b013e318299f0fb.
  • Nagao K, Yamaguchi S, Matsuyama H, Korenaga Y, Hirata H, Yoshihiro S, et al. Allelic loss of 3p25 associated with alterations of 5q22.3 approximately q23.2 may affect the prognosis of conventional renal cell carcinoma. Cancer Genet Cytogenet. 2005;160(1):43–48. Cited in: PMID: 15949569. doi:10.1016/j.cancergencyto.2004.11.015.
  • Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99(12):4638–4641. Cited in: PMID: 12036901. doi:10.1182/blood.v99.12.4638.
  • Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene. 2009;28(39):3429–3441. Cited in: PMID: 19597464. doi:10.1038/onc.2009.207.
  • Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13(1):78–83. Cited in: PMID: 17159988. doi:10.1038/nm1512.
  • Kojima K, Nakamura T, Ohbu M, Katoh H, Ooizumi Y, Igarashi K, et al. Cysteine dioxygenase type 1 (CDO1) gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer. PLoS One. 2018;13(5):e0194785. Cited in: PMID: 29746493. doi:10.1371/journal.pone.0194785.
  • Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, et al. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics. 2016;11(12):871–880. Cited in: PMID: 27689475; doi:10.1080/15592294.2016.1241931.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.